Over 1 in 4 drugs approved in US delayed by FDA complete response letters
This article was originally published in SRA
More than one in four drugs approved by the US Food and Drug Administration between fiscal years 2009 and 2012 were hit with complete response letters (CRLs) from the agency during the review process and had to be resubmitted before they were finally approved1.
You may also be interested in...
Health technology assessment body NICE is consulting on draft guidance that recommends Axonics' device for overactive bladder.
The risk of developing meningioma with cyproterone-containing medicines is rare, but it is serious enough to merit restrictions on how such products are used, according to the European Medicines Agency.
The European Medicines Agency has agreed to review pan-EU marketing applications for a number of new medicines.